



**Influenza Reagent  
influenza virus infectious NYMC BX-35  
NIBSC code: 15/300  
Instructions for use  
(Version 2.0, Dated 19/05/2016)**

### 1. INTENDED USE

Reagent 15/300 is prepared from NYMC BX-35 which was processed for freeze drying in 250 µl volumes as described by Campbell, PJ, Journal of Biological Standardisation, 1974, 2, 249-267. The derivation and known passage history of NYMC BX-35 is attached.

### 2. CAUTION

**This preparation is not for administration to humans or animals in the human food chain.**

The material is not of human or bovine origin. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

### 3. UNITAGE

No unitage is assigned to this material

### 4. CONTENTS

Country of origin of biological material: United Kingdom.  
Each ampoule contains 250µl (nominal) of infectious influenza virus as freeze dried allantoic fluid from embryonated SPF hen's eggs.

### 5. STORAGE

Store in the dark at -20°C or below

**Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.**

### 6. DIRECTIONS FOR OPENING

DIN ampoules have an 'easy-open' coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufacturers instructions provided with the ampoule breaker.

### 7. USE OF MATERIAL

Reconstitute the contents of one ampoule of reagent with 250µl of sterile distilled water. Leave for a minimum of 5 minutes before use to allow for complete solution of freeze dried material. A range of dilutions (e.g. 10<sup>-3</sup> to 10<sup>-5</sup>) should be made in a suitable medium for initial cultivation.

### 8. STABILITY

Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials.

### 9. REFERENCES

NA

### 10. ACKNOWLEDGEMENTS

NA

### 11. FURTHER INFORMATION

Further information can be obtained as follows:  
This material: [enquiries@nibsc.org](mailto:enquiries@nibsc.org)  
WHO Biological Standards:  
<http://www.who.int/biologicals/en/>  
JCTLM Higher order reference materials:  
<http://www.bipm.org/en/committees/jc/jctlm/>  
Derivation of International Units:  
[http://www.nibsc.org/standardisation/international\\_standards.aspx](http://www.nibsc.org/standardisation/international_standards.aspx)  
Ordering standards from NIBSC:  
<http://www.nibsc.org/products/ordering.aspx>  
NIBSC Terms & Conditions:  
[http://www.nibsc.org/terms\\_and\\_conditions.aspx](http://www.nibsc.org/terms_and_conditions.aspx)

### 12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to [enquiries@nibsc.org](mailto:enquiries@nibsc.org)

### 13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

### 14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties	
Physical appearance: White powder	Corrosive: No
Stable: Yes	Oxidising: No
Hygroscopic: No	Irritant: No
Flammable: No	Handling: See caution, Section 2
Other (specify):	Live influenza virus
Toxicological properties	
Effects of inhalation:	Likelihood of influenza virus infection
Effects of ingestion:	Not established, avoid ingestion
Effects of skin absorption:	Not established, avoid contact with skin
Suggested First Aid	
Inhalation:	Seek medical advice
Ingestion:	Seek medical advice
Contact with eyes:	Wash with copious amounts of water. Seek medical advice
Contact with skin:	Wash thoroughly with water.
Action on Spillage and Method of Disposal	
Spillage of contents should be taken up with absorbent material wetted with a virucidal agent. Rinse area with an appropriate virucidal agent followed by water. Absorbent materials used to treat spillage should be treated as biologically hazardous waste.	

### 15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at [http://www.nibsc.org/About\\_Us/Terms\\_and\\_Conditions.aspx](http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx) or upon



request by the Recipient) (“Conditions”) apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient’s attention is drawn in particular to the provisions of clause 11 of the Conditions.

**16. INFORMATION FOR CUSTOMS USE ONLY**

<b>Country of origin for customs purposes*:</b> United Kingdom * Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.
<b>Net weight:</b> NA
<b>Toxicity Statement:</b> Non-toxic
<b>Veterinary certificate or other statement</b> if applicable.
<b>Attached:</b> No

**Derivation of NYMC BX-35 (post mixed infection)**

Passage	Lot	Laboratory
E1-E8		NYMC, New York, USA
E9	E#5873	NYMC, New York, USA
E10	32310	NIBSC, Hertfordshire, UK
E11	41950	NIBSC, Hertfordshire, UK

Sterility: No visible contamination was detected in a variety of media (tryptose soya broth, thioglycolate broth, Sabouraud’s broth and blood agar plates) after 14 days incubation.

The HA and NA sequence of this virus is available on GISAID with the accession number EPI\_ISL\_217973





## Derivation of NYMC BX-35 B/Brisbane/60/2008 (Victoria lineage) - like High Yield Reassortant (1:2:5) with B/Lee/40 NP and B/Panama/45/90 PB2 and M genes

Exper. # 4647 8/14/09

BX-33B: B/Brisbane/60/2008-like reassortant with B/Panama/45/90 PB2 and M genes

Post-reassortment  
Passage No.





HA and NA identified as B/Brisbane/60/2008 by RT-PCR/RFLP analysis of HA and NA genes. RT-PCR/RFLP analysis also identified PB1, PA and NS genes as B/Brisbane/60/2008, PB2 and M genes as B/Panama/45/90, and NP gene as B/Lee/40 SPAFAS eggs used for all reassortant passages. HA titer was tested using chicken red blood cells at room temp.